Filtros de búsqueda

Lista de obras de George Wilding

A Festschrift in Honor of Edward M. Messing, MD, FACS

artículo científico publicado en 2018

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

artículo científico publicado en 2013

A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer

artículo científico publicado en 2004

A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors

artículo científico publicado en 2009

A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

artículo científico publicado en 2010

A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.

artículo científico publicado en 2016

A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

artículo científico publicado en 2014

A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer.

artículo científico publicado en 2011

A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer ⬇️

artículo científico publicado el 11 de abril de 2011

A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

artículo científico publicado en 2013

A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies

artículo científico publicado en 2009

A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer

artículo científico publicado en 2005

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

artículo científico publicado en 2008

A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors

artículo científico publicado en 2008

A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer ⬇️

artículo científico publicado el 17 de julio de 2013

A phase I study of Topotecan, as a radiosensitizer, for thoracic malignancies

artículo científico publicado en 2004

A phase I study of Triapine in combination with doxorubicin in patients with advanced solid tumors

artículo científico publicado en 2008

A phase I study of a DNA vaccine targeting prostatic Acid phosphatase in patients with stage D0 prostate cancer

artículo científico publicado en 2005

A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer

artículo científico publicado en 2015

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

artículo científico publicado en 2013

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

artículo científico publicado en 2009

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

artículo científico publicado en 2014

A phase I trial of MK-0731, a Kinesin Spindle Protein (KSP) inhibitor, in patients with solid tumors ⬇️

artículo científico publicado el 22 de marzo de 2011

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

artículo científico publicado en 2008

A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

artículo científico publicado en 2006

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

artículo científico publicado en 2004

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days

artículo científico publicado en 2004

A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer

artículo científico publicado en 2005

A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).

artículo científico publicado en 2003

A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).

artículo científico publicado en 2010

A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate ⬇️

artículo científico publicado el 22 de diciembre de 2010

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802 ⬇️

artículo científico publicado el 6 de febrero de 2011

A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer

artículo científico publicado en 2007

A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy

artículo científico publicado en 2013

A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.

artículo científico publicado en 2010

A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model

artículo científico publicado en 2009

A test of rats' tolerance for 3beta-acetoxyandrosta-1,5-dien-17-one ethylene ketal (ADEK), a new anti-androgen

artículo científico publicado en 2008

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

artículo científico publicado en 2006

Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.

artículo científico publicado en 2002

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

artículo científico publicado en 2005

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

artículo científico publicado en 2007

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

artículo científico publicado en 2016

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study

scientific article published on 01 May 2007

Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy

artículo científico publicado en 2009

An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer

artículo científico publicado en 2009

Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.

artículo científico publicado en 2003

Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells

artículo científico publicado en 2010

Angiogenesis inhibitors in genitourinary cancers

artículo científico publicado en 2003

Assessment of adherence and relative dose intensity with oral chemotherapy in oncology clinical trials at an academic medical center

artículo científico publicado en 2017

Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).

artículo científico publicado en 2015

Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis

artículo científico publicado en 2013

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

artículo científico publicado en 2007

Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement

artículo científico publicado en 2017

Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study

artículo científico publicado en 2004

Cyclopropane-Containing Polyamine Analogues Are Efficient Growth Inhibitors of a Human Prostate Tumor Xenograft in Nude Mice ⬇️

artículo científico publicado el 9 de octubre de 2003

Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electron Paramagnetic Resonance

artículo científico publicado en 2011

Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.

artículo científico publicado en 2009

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

artículo científico publicado en 2008

Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial

artículo científico publicado en 2013

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

artículo científico publicado en 2008

Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study

artículo científico publicado en 2005

Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer ⬇️

artículo científico publicado el 23 de julio de 2011

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

artículo científico publicado en 2015

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test

artículo científico publicado en 2007

Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805

artículo científico publicado en 2015

Effects of a monoclonal anti-alphavbeta3 integrin antibody on blood vessels - a pharmacodynamic study

artículo científico publicado en 2006

Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine

artículo científico publicado en 2007

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

artículo científico publicado en 2004

Endothelin receptor antagonists in cancer therapy

artículo científico publicado en 2007

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

artículo científico publicado en 2012

Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human tumors

artículo científico publicado en 2009

Expression of spermidine/spermine N(1) -acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis

artículo científico publicado en 2015

Gemcitabine, Paclitaxel, and piritrexim: a phase I study

artículo científico publicado en 2003

Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1α,24‐dihydroxyvitamin D2 ⬇️

artículo científico publicado el 15 de mayo de 2003

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

artículo científico publicado en 2006

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

artículo científico publicado en 2012

In Reply

article published in 2008

Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells

artículo científico publicado en 2005

Inhibitor of p52 NF-κB subunit and androgen receptor (AR) interaction reduces growth of human prostate cancer cells by abrogating nuclear translocation of p52 and phosphorylated AR(ser81).

artículo científico publicado en 2015

Intermittent versus continuous androgen deprivation in prostate cancer

artículo científico publicado en 2013

JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells

artículo científico publicado en 2008

Leinamycin E1 acting as an anticancer prodrug activated by reactive oxygen species

artículo científico publicado en 2015

Newer therapies in advanced prostate cancer

artículo científico publicado en 2004

Novel antioxidant technology for prostate cancer chemoprevention and treatment

artículo científico publicado en 2006

Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2011

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

artículo científico publicado en 2009

Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group

artículo científico publicado en 2003

Period analysis of prostate cancer survival

scientific article published on 30 November 2004

Pharmacodynamic Study Using FLT PET/CT in Patients with Renal Cell Cancer and Other Solid Malignancies Treated with Sunitinib Malate ⬇️

artículo científico publicado el 28 de octubre de 2011

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial

artículo científico publicado en 2017

Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2007

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2008

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

scientific article published on September 2009

Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.

artículo científico publicado en 2002

Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor

artículo científico publicado en 2004

Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.

artículo científico publicado en 2002

Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy

artículo científico publicado en 2002

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

artículo científico publicado en 2002

Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors

artículo científico publicado en 2010

Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer

artículo científico publicado en 2011

Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors

artículo científico publicado en 2003

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design ⬇️

artículo científico publicado el 12 de enero de 2011

Phase I study of docetaxel and topotecan in patients with advanced malignancies

artículo científico publicado en 2005

Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy

artículo científico publicado en 2002

Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors

artículo científico publicado en 2005

Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer

artículo científico publicado en 2002

Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies

artículo científico publicado en 2009

Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion

artículo científico publicado en 2005

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

artículo científico publicado en 2009

Phase I trial of perillyl alcohol administered four times daily continuously

artículo científico publicado en 2003

Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma

artículo científico publicado en 2009

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

artículo científico publicado en 2005

Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors

artículo científico publicado en 2004

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer ⬇️

artículo científico publicado el 31 de diciembre de 2011

Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors

artículo científico publicado en 2007

Phase II Trial of Weekly Ixabepilone in Men With Metastatic Castrate-Resistant Prostate Cancer (E3803): A Trial of the Eastern Cooperative Oncology Group ⬇️

artículo científico publicado el 3 de marzo de 2012

Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group

artículo científico publicado en 2006

Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin ⬇️

artículo científico publicado el 17 de enero de 2013

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2004

Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer

artículo científico publicado en 2003

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

artículo científico publicado en 2009

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study

artículo científico publicado en 2005

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer

artículo científico publicado en 2009

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

scientific article published on 01 May 2006

Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2008

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2002

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2002

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2003

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer ⬇️

artículo científico publicado el 1 de agosto de 2003

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

artículo científico publicado en 2003

Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium

artículo científico publicado en 2004

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma ⬇️

artículo científico publicado el 7 de junio de 2011

Piritrexim in advanced, refractory carcinoma of the urothelium (E3896): a phase II trial of the Eastern Cooperative Oncology Group

artículo científico publicado en 2002

Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

artículo científico publicado en 2010

Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials

artículo científico publicado en 2015

Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).

artículo científico publicado en 2010

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

artículo científico publicado en 2009

Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer

artículo científico publicado en 2007

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

artículo científico publicado en 2004

Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma

article

Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer

artículo científico publicado en 2006

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

artículo científico publicado en 2002

Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer

artículo científico publicado en 2008

Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer

artículo científico publicado en 2014

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

artículo científico publicado en 2006

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer

artículo científico publicado en 2009

Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer

artículo científico publicado en 2012

Sunitinib efficacy against advanced renal cell carcinoma

artículo científico publicado en 2007

Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results

artículo científico publicado en 2010

Sunitinib in patients with metastatic renal cell carcinoma

artículo científico publicado en 2006

Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression

artículo científico publicado en 2014

The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

artículo científico publicado en 2010

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

artículo científico publicado en 2013

Therapy-Induced Senescence in Cancer ⬇️

artículo científico publicado el 21 de septiembre de 2010

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

artículo científico publicado en 2016

Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study

artículo científico publicado en 2008

Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study

artículo científico publicado en 2009

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes ⬇️

artículo científico publicado el 1 de agosto de 2013

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda